Logo of Botanix Pharmaceuticals (ASX:BOT)Latest Botanix Pharmaceuticals (ASX:BOT) News

Page 2
Page 2 of 3

Botanix Boosts Sofdra Sales 171% but Posts $33M Half-Year Loss

Botanix Pharmaceuticals reports a surge in Sofdra sales driving revenue to $16.5 million, yet the company records a $33.2 million loss amid expanded marketing and operational costs. A $45 million capital raise aims to support growth and supply chain improvements.
Ada Torres
27 Feb 2026

Market Wrap - Week 8 (16 Feb -> 20 Feb) 2026

Deal headlines and big drill hits shared the stage with a brutal sell-off in a handful of tiny raisings. The week’s biggest winners were backed by clear news; the biggest losers showed what happens when buyers vanish after a halt.
Logan Eniac
21 Feb 2026

Healthcare Wrap - Week 8 (16 Feb -> 20 Feb) 2026

Two capital raisings and one brutal reset set the tone, even as several companies posted clean growth or strong clinical updates. Radiopharmaceuticals kept delivering good news, but investors still punished supply-chain and cash needs fast.
Logan Eniac
21 Feb 2026

Botanix Pharmaceuticals Raises A$45 Million to Fuel Sofdra® Growth and Cut API Costs

Botanix Pharmaceuticals has launched a A$45 million capital raising to support the expansion of its dermatology product Sofdra®, while negotiating to reduce active pharmaceutical ingredient costs by up to 40%. The raising includes a two-tranche placement and a security purchase plan, with options offered to investors.
Ada Torres
17 Feb 2026

Botanix Raises A$45 Million to Secure Supply Chain and Boost Sofdra Growth

Botanix Pharmaceuticals has secured approximately A$45 million through a two-tranche placement and an underwritten security purchase plan to fund API purchases, derisk its supply chain, and accelerate growth of its flagship product Sofdra.
Ada Torres
17 Feb 2026

Healthcare Wrap - Week 5 (26 Jan -> 30 Jan) 2026

A handful of healthcare names did the heavy lifting this week, driven by FDA wins, guideline upgrades, and big shifts in sales and cashflow. The flip side: several clinical-stage stocks fell hard as investors stayed picky about near-term proof and funding.
Logan Eniac
31 Jan 2026

Botanix Sofdra Sales Surge 28% Amid Strategic Sales Force Expansion

Botanix Pharmaceuticals reported a robust 28% increase in net revenue for Sofdra in Q2 FY26, driven by a 24% rise in prescriptions and a growing US sales team. The company maintains a strong cash position while navigating higher operating costs.
Ada Torres
27 Jan 2026

Botanix Boosts Sofdra Sales 50% with Expanded US Sales Force

Botanix Pharmaceuticals reports a strong start to FY26 with a 50% surge in Sofdra prescriptions and a 65% rise in net revenue, underpinned by a larger sales team and operational efficiencies.
Ada Torres
20 Oct 2025

Botanix’s ECCLOCK® Gel Gains South Korean Approval, Launch Set for 2026

Botanix Pharmaceuticals’ ECCLOCK® gel, a treatment for excessive sweating, has secured regulatory approval in South Korea, paving the way for a commercial launch in early 2026.
Ada Torres
5 Sept 2025

Botanix Reports $5.76M Revenue Amid $86.4M Loss as Sofdra Launch Accelerates

Botanix Pharmaceuticals posted a sharp revenue increase driven by its new hyperhidrosis treatment Sofdra, yet reported a substantial net loss reflecting heavy investment in commercialisation. The company’s strong cash position underpins its path to profitability.
Ada Torres
29 Aug 2025

Botanix Clarifies $25M Sales Surge and ASX Disclosure Timing

Botanix Pharmaceuticals confirms material sales and prescription growth data, explaining the timing of its ASX disclosures amid share price fluctuations.
Ada Torres
31 July 2025

Botanix’s Sofdra Sales Surge Fuels $40M Capital Raise and $30M Debt Facility

Botanix Pharmaceuticals reports a strong commercial ramp-up for Sofdra™, with net revenue jumping from $0.7 million to $4.3 million in one quarter, supported by a $40 million capital raise and a $30 million debt facility.
Ada Torres
28 July 2025